956034-06-3

Basic information

• Product Name: FURO[3,2-D]PYRIMIDINE-2,4-DIOL
• Synonyms: FURO[3,2-D]PYRIMIDINE-2,4-DIOL;Furo[3,2-d]pyrimidine-2,4(1H,3H)-dione
• CAS NO: 956034-06-3
• Molecular Formula: C₆H₄N₂O₃
• Molecular Weight: 152.10800
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 956034-06-3.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.461g/cm3
• Refractive Index: 1.548
• Storage Temp.: 2-8°C
• CAS DataBase Reference: FURO[3,2-D]PYRIMIDINE-2,4-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: FURO[3,2-D]PYRIMIDINE-2,4-DIOL(956034-06-3)
• EPA Substance Registry System: FURO[3,2-D]PYRIMIDINE-2,4-DIOL(956034-06-3)

Safety Data

• Hazardous Substances Data: 956034-06-3(Hazardous Substances Data)

Usage

General Description

Furo[3,2-d]pyrimidine-2,4-diol is a heterocyclic chemical compound with a fused pyrimidine and furan ring system. It is a derivative of pyrimidine and contains two hydroxyl groups at positions 2 and 4 on the pyrimidine ring. Furo[3,2-d]pyrimidine-2,4-diol has potential use in organic synthesis and pharmaceutical research due to its unique structural features and potential biological activities. It can serve as a starting material for the synthesis of various biologically active molecules and is of interest for medicinal chemistry applications. Furo[3,2-d]pyrimidine-2,4-diol has the potential to exhibit diverse pharmacological properties, making it valuable for drug development and discovery.

InChI:InChI=1/C6H4N2O3/c9-5-4-3(1-2-11-4)7-6(10)8-5/h1-2H,(H2,7,8,9,10)

Upstream product

• 956034-05-2 ethyl 3-ureidofuran-2-carboxylate 
• 956034-03-0 methyl 3-((tert-butoxycarbonyl)amino)furan-2-carboxylate 
• 956034-04-1 methyl 3-aminofuran-2-carboxylate 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 1093066-63-7 methyl 3-ureidofuran-2-carboxylate 

Downstream Products

• 956034-07-4 2,4-dichloro-furo[3,2-d]pyrimidine 
• 1312929-44-4 sodium 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylate 
• 1312929-46-6 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-N-(3-methoxyphenyl)-1H-pyrazole-5-carboxamide 
• 1312929-26-2 N-(3-methoxyphenyl)-3-(2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide 

Relevant articles and documents

Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer

PARP inhibitors have achieved great success in cancers with BRCA mutations, but only a small portion of patients carry BRCA mutations, which results in their narrow indication spectrum. Recently, emerging evidence has demonstrated that combinations of PARP and PI3K inhibitors could evoke unanticipated synergistic effects in various cancers, even including BRCA-proficient ones. In this work, a series of PARP/PI3K dual inhibitors were designed, synthesized, and evaluated for their biological activities. It was found that compounds 9a and 23a exhibited excellent inhibitory activities against PARP-1 (9a: IC50 = 1.57 nM, 23a: IC50 = 0.91 nM) and PI3Kα (9a: IC50 = 2.0 nM, 23a: IC50 = 1.5 nM), and showed promising antiproliferative activities against both BRCA-deficient (HCT-116, HCC-1937) and BRCA-proficient (SW620, MDA-MB-231/468) tumor cells. 9a and 23a also exhibited considerable in vivo antitumor efficacy in an MDA-MB-468 xenograft mouse model, with TGI values of 56.39% and 48.77%, respectively. Additionally, 23a possessed promising profiles including high kinase selectivity and low cardiotoxicity. Overall, this work indicates 9a and 23a might be potential PARP/PI3K dual inhibitors for cancer therapy and deserve further research.

NOVEL PROCESS FOR PREPARING NOVEL THIOXO FUROPYRIMIDINONE DERIVATIVES AND INTERMEDIATES USED THEREIN

The present invention relates to a preparation method of 2-thioxo furopyrimidin-4-one represented by chemical formula 1 and an intermediate product used thereto. More particularly, the preparation method of the present invention obtains a thiourea carboxy

Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors

G9a is a histone lysine methyltransferase (HKMT) involved in epigenetic regulation via the installation of histone methylation marks. 6,7-Dimethoxyquinazoline analogues, such as BIX-01294, are established as potent, substrate competitive inhibitors of G9a. With an objective to identify novel chemotypes for substrate competitive inhibitors of G9a, we have designed and synthesised a range of heterocyclic scaffolds, and investigated their ability to inhibit G9a. These studies have led to improved understanding of the key pharmacophoric features of BIX-01294 and the identification of a new core quinoline inhibitory scaffold, which retains excellent potency and high selectivity. Molecular docking was carried out to explain the observed in vitro data. This journal is